ArticleScientific reports2025
Serum cytokine inflammatory profile in children with ulcerative colitis during 6-month follow-up.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The involvement of inflammation in the development of ulcerative colitis (UC) is significant. Therefore, the purpose of our study was to evaluate the serum levels of selected cytokines, chemokines and growth factors in children at the time of diagnosis/exacerbation of UC (T0), as well as 3 (T1) and 6 (T2) months after the introduction or change of treatment, and to assess their usefulness in predicting the course of the disease and the need for treatment intensification. Thirty-three children (study group) with UC, including 25 with new diagnoses of UC (ndUC), and 29 healthy controls (Ctr) were included in the study. Serum cytokine panels were measured at three time points: T0, T1, and T2 using multiplex ELISA method. At T0, significantly higher levels of IL-8, IL-17, eotaxin, and granulocyte colony-stimulating factor (G-CSF) were observed in both the UC and ndUC groups. At T1, higher levels of IL-17, eotaxin, and fibroblast growth factor (FGF) were noted in the study group compared to controls. When the group was stratified according to clinical activity at 6 months, IL-17, eotaxin, and FGF levels at T0 were higher in patients who achieved Pediatric Ulcerative Colitis Activity Index (PUCAI) < 10 compared to those with PUCAI ≥ 10. However, these associations should be interpreted with caution due to the heterogeneity of treatment interventions, which likely influenced the outcomes. Our exploratory analyses indicate that serum cytokines may reflect disease activity and may help in understanding clinical outcomes in pediatric UC, although prospective studies with standardized treatment protocols are needed to confirm their predictive value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.